GB0024795D0 - Pyrazole derivatives for the treatment of viral diseases - Google Patents

Pyrazole derivatives for the treatment of viral diseases

Info

Publication number
GB0024795D0
GB0024795D0 GBGB0024795.7A GB0024795A GB0024795D0 GB 0024795 D0 GB0024795 D0 GB 0024795D0 GB 0024795 A GB0024795 A GB 0024795A GB 0024795 D0 GB0024795 D0 GB 0024795D0
Authority
GB
United Kingdom
Prior art keywords
treatment
viral diseases
pyrazole derivatives
pyrazole
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0024795.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to GBGB0024795.7A priority Critical patent/GB0024795D0/en
Publication of GB0024795D0 publication Critical patent/GB0024795D0/en
Priority to US09/956,656 priority patent/US6699887B2/en
Priority to YU27203A priority patent/YU27203A/sh
Priority to PL01362918A priority patent/PL362918A1/xx
Priority to KR10-2003-7004984A priority patent/KR100534158B1/ko
Priority to RU2003112610/04A priority patent/RU2270832C2/ru
Priority to CNA2005100088329A priority patent/CN1680333A/zh
Priority to JP2002534293A priority patent/JP4015548B2/ja
Priority to MXPA03003070A priority patent/MXPA03003070A/es
Priority to HR20030251A priority patent/HRP20030251A2/hr
Priority to AU2002221651A priority patent/AU2002221651B2/en
Priority to CNB018171710A priority patent/CN1191239C/zh
Priority to HK04103975.9A priority patent/HK1061021B/xx
Priority to BR0114483-9A priority patent/BR0114483A/pt
Priority to EP01986680A priority patent/EP1326843A1/en
Priority to CZ20031297A priority patent/CZ20031297A3/cs
Priority to NZ524740A priority patent/NZ524740A/en
Priority to IL15487501A priority patent/IL154875A0/xx
Priority to HU0302722A priority patent/HUP0302722A2/hu
Priority to CA002423515A priority patent/CA2423515A1/en
Priority to AU2165102A priority patent/AU2165102A/xx
Priority to PCT/EP2001/011474 priority patent/WO2002030907A1/en
Priority to ARP010104697A priority patent/AR030858A1/es
Priority to PE2001000993A priority patent/PE20020750A1/es
Priority to UY26956A priority patent/UY26956A1/es
Priority to GT200100201A priority patent/GT200100201A/es
Priority to PA20018530301A priority patent/PA8530301A1/es
Priority to ZA200302519A priority patent/ZA200302519B/en
Priority to MA27096A priority patent/MA26951A1/fr
Priority to EC2003004547A priority patent/ECSP034547A/es
Priority to NO20031615A priority patent/NO20031615L/no
Priority to US10/766,712 priority patent/US7183296B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB0024795.7A 2000-10-10 2000-10-10 Pyrazole derivatives for the treatment of viral diseases Ceased GB0024795D0 (en)

Priority Applications (32)

Application Number Priority Date Filing Date Title
GBGB0024795.7A GB0024795D0 (en) 2000-10-10 2000-10-10 Pyrazole derivatives for the treatment of viral diseases
US09/956,656 US6699887B2 (en) 2000-10-10 2001-09-20 Anti-HIV pyrazole derivatives
PCT/EP2001/011474 WO2002030907A1 (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases
EP01986680A EP1326843A1 (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases
IL15487501A IL154875A0 (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases
KR10-2003-7004984A KR100534158B1 (ko) 2000-10-10 2001-10-04 바이러스성 질환의 치료를 위한 피라졸 유도체
RU2003112610/04A RU2270832C2 (ru) 2000-10-10 2001-10-04 Производные пиразола для лечения вирусных заболеваний
CNA2005100088329A CN1680333A (zh) 2000-10-10 2001-10-04 用于治疗病毒性疾病的吡唑衍生物
JP2002534293A JP4015548B2 (ja) 2000-10-10 2001-10-04 ウイルス性疾患の処置のためのピラゾール誘導体
MXPA03003070A MXPA03003070A (es) 2000-10-10 2001-10-04 Derivados de pirazol para tratamiento de enfermedades virales.
HR20030251A HRP20030251A2 (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases
AU2002221651A AU2002221651B2 (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases
CNB018171710A CN1191239C (zh) 2000-10-10 2001-10-04 用于治疗病毒性疾病的吡唑衍生物
HK04103975.9A HK1061021B (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases
BR0114483-9A BR0114483A (pt) 2000-10-10 2001-10-04 Derivado de pirazol para tratamento de doenças viróticas
YU27203A YU27203A (sh) 2000-10-10 2001-10-04 Pirazol derivati za tretiranje virusnih oboljenja
CZ20031297A CZ20031297A3 (cs) 2000-10-10 2001-10-04 Pyrazolové deriváty pro léčbu virových onemocnění
NZ524740A NZ524740A (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases mediated by the human immunodeficiency virus (HIV)
PL01362918A PL362918A1 (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases
HU0302722A HUP0302722A2 (hu) 2000-10-10 2001-10-04 Pirazolszármazékok, vírusos betegségek kezelésére és a vegyületeket tartalmazó gyógyszerkészítmények, továbbá pirazolszármazékok alkalmazása gyógyszerkészítmények előállítására
CA002423515A CA2423515A1 (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases
AU2165102A AU2165102A (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases
PE2001000993A PE20020750A1 (es) 2000-10-10 2001-10-05 Derivados de pirazol
ARP010104697A AR030858A1 (es) 2000-10-10 2001-10-05 DERIVADOS DE PIRAZOL PARA EL TRATAMIENTO DE ENFERMEDADES VíRICAS
UY26956A UY26956A1 (es) 2000-10-10 2001-10-09 Derivados del pirazol para el tratamiento de enfermedades virales
GT200100201A GT200100201A (es) 2000-10-10 2001-10-09 Derivados de pirazol para el tratamiento der enfermedades viricas.
PA20018530301A PA8530301A1 (es) 2000-10-10 2001-10-09 Derivados de pirazol para el tratamiento de enfermedades virales
ZA200302519A ZA200302519B (en) 2000-10-10 2003-03-31 Pyrazole derivatives for treatment of viral diseases.
MA27096A MA26951A1 (fr) 2000-10-10 2003-04-07 Derives de pyrazole pour le traitement de maladies virales
EC2003004547A ECSP034547A (es) 2000-10-10 2003-04-08 Derivados de pirazol para el tratamiento de enfermedades virales
NO20031615A NO20031615L (no) 2000-10-10 2003-04-09 Pyrazol-derivater for behandling av virus-sykdommer
US10/766,712 US7183296B2 (en) 2000-10-10 2004-01-27 Anti-HIV pyrazole derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0024795.7A GB0024795D0 (en) 2000-10-10 2000-10-10 Pyrazole derivatives for the treatment of viral diseases

Publications (1)

Publication Number Publication Date
GB0024795D0 true GB0024795D0 (en) 2000-11-22

Family

ID=9900999

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0024795.7A Ceased GB0024795D0 (en) 2000-10-10 2000-10-10 Pyrazole derivatives for the treatment of viral diseases

Country Status (28)

Country Link
US (2) US6699887B2 (https=)
EP (1) EP1326843A1 (https=)
JP (1) JP4015548B2 (https=)
KR (1) KR100534158B1 (https=)
CN (2) CN1680333A (https=)
AR (1) AR030858A1 (https=)
AU (2) AU2002221651B2 (https=)
BR (1) BR0114483A (https=)
CA (1) CA2423515A1 (https=)
CZ (1) CZ20031297A3 (https=)
EC (1) ECSP034547A (https=)
GB (1) GB0024795D0 (https=)
GT (1) GT200100201A (https=)
HR (1) HRP20030251A2 (https=)
HU (1) HUP0302722A2 (https=)
IL (1) IL154875A0 (https=)
MA (1) MA26951A1 (https=)
MX (1) MXPA03003070A (https=)
NO (1) NO20031615L (https=)
NZ (1) NZ524740A (https=)
PA (1) PA8530301A1 (https=)
PE (1) PE20020750A1 (https=)
PL (1) PL362918A1 (https=)
RU (1) RU2270832C2 (https=)
UY (1) UY26956A1 (https=)
WO (1) WO2002030907A1 (https=)
YU (1) YU27203A (https=)
ZA (1) ZA200302519B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1335898B1 (en) * 2000-09-29 2005-11-23 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
GB0113524D0 (en) * 2001-06-04 2001-07-25 Hoffmann La Roche Pyrazole derivatives
US7230025B2 (en) 2002-09-26 2007-06-12 Pfizer, Inc. Pyrazole derivatives
BR0314759A (pt) 2002-09-26 2005-07-26 Pfizer Derivados de pirazol
CA2497333A1 (en) * 2002-09-26 2004-04-08 Pfizer Inc. Pyrazole derivatives as reverse transcriptase inhibitors
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
GB0223232D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
GB0223234D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
TW200423930A (en) * 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
BRPI0408704A (pt) 2003-03-24 2006-03-07 Hoffmann La Roche benzil-piridazinonas como inibidores de transcriptase reversa
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
MX2007000214A (es) * 2004-07-01 2007-05-10 Asubio Pharma Co Ltd Derivado de tienopirazol que tiene actividad inhibidora de pde 7.
US20070005049A1 (en) * 2005-06-30 2007-01-04 Comben Richard H Apparatus and Method of Treating Urinary Incontinence by Heating Urethra
MX2009000482A (es) * 2006-07-05 2009-01-27 Pfizer Prod Inc Compuestos terapeuticos.
CA2658984C (en) 2006-08-16 2014-12-02 Joshua Kennedy-Smith Non-nucleoside reverse transcriptase inhibitors
GB0713479D0 (en) * 2007-07-11 2007-08-22 Syngenta Participations Ag Substituted aromatic heterocyclic compounds as fungicides
RU2495878C2 (ru) 2007-12-21 2013-10-20 Ф.Хоффманн-Ля Рош Аг Гетероциклические антивирусные соединения
GB0823000D0 (en) * 2008-12-17 2009-01-28 Syngenta Participations Ag Isothiazole and pyrazole derivatives with plant growth regulating properties
CN102333781B (zh) 2009-02-25 2014-06-11 第一三共株式会社 三环吡唑并嘧啶衍生物
FR2951549B1 (fr) 2009-10-15 2013-08-23 Olivier Schussler Procede d'obtention de bioprotheses medicales implantables
EP2610259A4 (en) 2010-08-23 2014-01-08 Daiichi Sankyo Co Ltd FREE CRYSTAL OF A TRICYCLIC PYRAZOLOPYRIMIDINE DERIVATIVE
TW201213333A (en) 2010-08-23 2012-04-01 Daiichi Sankyo Co Ltd Crystal forms of tricyclic pyrazolopyrimidine derivative
US9695127B2 (en) 2012-11-08 2017-07-04 University of Pittsburgh—of the Commonwealth System of Higher Education Compounds for treating HIV and methods for using the compounds
US9925190B2 (en) 2015-02-16 2018-03-27 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecules targeting HIV-1 Nef
EP3778583B1 (en) 2018-03-30 2025-06-18 Sumitomo Chemical Company, Limited Heterocyclic compound and arthropod pest control composition containing same
US20220380341A1 (en) * 2018-10-18 2022-12-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibitors of hiv-1 nef for the treatment of hiv disease
FR3121927B1 (fr) 2021-04-19 2023-03-31 Eiffage Genie Civil Terrassement Procédé d’inertage des boues d’excavation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627423A4 (en) 1992-01-22 1995-02-15 Nissan Chemical Ind Ltd SUBSTITUTED PYRAZOLE DERIVATIVES AND BACTERICIDES FOR AGRICULTURE AND GARDENING.
US6005109A (en) 1997-10-30 1999-12-21 Pflizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
KR100190730B1 (ko) * 1992-12-17 1999-06-01 디. 제이. 우드, 스피겔 알렌 제이 부신피질 호르몬 유리인자(crf) 길항물질로서 치환된 피라졸
TW336932B (en) * 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
DK0674624T3 (da) * 1992-12-17 1999-09-13 Pfizer Pyrazoler med CRF-antagonistisk aktivitet
WO2006027423A1 (fr) * 2004-08-09 2006-03-16 Simag Developpement Dispositif de saisie comportant un capteur optique suivi d’un moyen de filtrage

Also Published As

Publication number Publication date
MXPA03003070A (es) 2003-07-14
NO20031615L (no) 2003-05-23
HRP20030251A2 (en) 2005-02-28
US20040192752A1 (en) 2004-09-30
ECSP034547A (es) 2003-05-26
US7183296B2 (en) 2007-02-27
GT200100201A (es) 2002-05-23
JP4015548B2 (ja) 2007-11-28
CZ20031297A3 (cs) 2004-01-14
EP1326843A1 (en) 2003-07-16
NZ524740A (en) 2005-09-30
US6699887B2 (en) 2004-03-02
KR100534158B1 (ko) 2005-12-06
CN1469865A (zh) 2004-01-21
RU2003112610A (ru) 2005-02-20
AU2165102A (en) 2002-04-22
RU2270832C2 (ru) 2006-02-27
CA2423515A1 (en) 2002-04-18
ZA200302519B (en) 2004-06-30
US20030018197A1 (en) 2003-01-23
HK1061021A1 (en) 2004-09-03
CN1191239C (zh) 2005-03-02
MA26951A1 (fr) 2004-12-20
UY26956A1 (es) 2002-04-26
AU2002221651B2 (en) 2006-10-19
JP2004511469A (ja) 2004-04-15
CN1680333A (zh) 2005-10-12
NO20031615D0 (no) 2003-04-09
PE20020750A1 (es) 2002-08-21
AR030858A1 (es) 2003-09-03
WO2002030907A1 (en) 2002-04-18
PA8530301A1 (es) 2002-07-30
BR0114483A (pt) 2003-07-01
PL362918A1 (en) 2004-11-02
YU27203A (sh) 2006-05-25
IL154875A0 (en) 2003-10-31
HUP0302722A2 (hu) 2003-12-29
KR20030046492A (ko) 2003-06-12

Similar Documents

Publication Publication Date Title
GB0024795D0 (en) Pyrazole derivatives for the treatment of viral diseases
PL362711A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases
IL150742A0 (en) Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease
IL196301A0 (en) Medicament for the treatment of hapatitis c
EE200300497A (et) Pürasoolderivaadid HIV raviks
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
PL376454A1 (en) 1-acyl-pyrrolidine derivatives for the treatment of viral infections
IL192991A0 (en) Use of tetrahydrocarbazole derivatives for the manufacture of medicanents for treating gonadotropin-releasing hormone
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU3009801A (en) Combinations of medicaments for treating viral diseases
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
HUP0401600A3 (en) Process for the preparation of 14-hydroxymorphine derivatives
GB0004531D0 (en) The treatment of respiratory diseases
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU2184202A (en) Imidazolone derivatives for the treatment of viral diseases
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.
IL151188A0 (en) Medicament for viral diseases
AU5611701A (en) Agent for the diagnosis and therapy of viral diseases
PT1698338E (pt) S-metil-di-hidro-ziprasidona para o tratamento de distúrbios psiquiátricos
AU2001262520A1 (en) Combined preparation for the treatment of neoplasic diseases
AU4453301A (en) Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis
AU1324002A (en) Treatment of demyelinating diseases
GB9926985D0 (en) Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and-cyanamides for the treatment of diseases
HK1057753A (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)